We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+51.45%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$198M
AUM Growth
–
Cap. Flow
+$157M
Cap. Flow %
79.6%
Top 10 Hldgs %
76.11%
Holding
22
New
21
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$20.2M
2
KITE
Kite Pharma, Inc.
KITE
+$18.5M
3
SAGE
Sage Therapeutics
SAGE
+$18.3M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$14.8M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$12.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 75.45%
2 Miscellaneous 24.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KITE
1
DELISTED
Kite Pharma, Inc.
KITE
$25.3M 12.79%
+438,400
New +$18.5M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$21.5M 10.89%
+384,348
New +$20.2M
RCPT
3
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$17.9M 9.04%
+145,801
New +$14.8M
MGNX icon
4
MacroGenics
MGNX
$263M
$15.9M 8.05%
+453,626
New +$11.3M
IRWD icon
5
Ironwood Pharmaceuticals
IRWD
$682M
$13.8M 6.98%
+1,074,600
New +$12.3M
KYNB
6
Kyntra Bio
KYNB
$32.5M
$10.9M 5.53%
+16,000
New +$10.3M
ATRA icon
7
Atara Biotherapeutics
ATRA
$92.3M
$10.1M 5.13%
+15,405
New +$9.41M
KIN
8
DELISTED
Kindred Biosciences, Inc.
KIN
$9.64M 4.88%
+1,294,431
New +$11M
SAGE
9
DELISTED
Sage Therapeutics
SAGE
$9.07M 4.59%
+491,044
New +$18.3M
KERX
10
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$8.33M 4.22%
+589,000
New +$9.13M
ASMB icon
11
Assembly Biosciences
ASMB
$694M
$7.94M 4.02%
+84,146
New +$8.29M
XENE icon
12
Xenon Pharmaceuticals
XENE
$5.81B
$6.48M 3.28%
+328,070
New +$4.82M
GNVC
13
DELISTED
GenVec, Inc.
GNVC
$4.13M 2.09%
+198,641
New +$3.84M
CALA
14
DELISTED
Calithera Biosciences, Inc
CALA
$4.07M 2.06%
+10,085
New +$2.63M
VTAE
15
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$3.44M 1.74%
+207,000
New +$3.03M
OMED
16
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$3.42M 1.73%
+157,038
New +$3.22M
PRTK
17
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.04M 1.54%
+78,958
New +$1.89M
FWP
18
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.08M 1.05%
+14,286
New +$2.06M
GYRE icon
19
Gyre Therapeutics
GYRE
$699M
$1.63M 0.82%
+787
New +$1.52M
HALO icon
20
CALL
Halozyme
HALO
$12B
$1.55M 0.78%
+160,700
New +$1.43M
ARRY
21
CALL
DELISTED
Array Biopharma Inc
ARRY
$1.08M 0.55%
+228,400
New +$903K

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for EcoR1 Capital, which disclosed 22 positions worth $198M. Its ten largest holdings account for 76% of the portfolio.

Its largest position is Clovis Oncology, Inc.: 384,348 shares worth $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, followed by Miscellaneous.

  • EcoR1 Capital's largest Q4 2014 buy was Clovis Oncology, Inc.: 384,348 shares worth $21.5M.
  • EcoR1 Capital's ten largest holdings make up 76% of its $198M portfolio in Q4 2014.
  • EcoR1 Capital disclosed 22 positions in Q4 2014, its first 13F filing on record.

Based on EcoR1 Capital's 13F filing for Q4 2014, filed 17 Feb 2015.